FDA approves Amphastar’s iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.
Latest Ratings for AMPH
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Piper Sandler | Maintains | Overweight | |
| Jan 2022 | Piper Sandler | Upgrades | Neutral | Overweight |
| Mar 2021 | Wells Fargo | Maintains | Equal-Weight |
